CHARLOTTE, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced an update to its previously announced voluntary warrant exchange program. Updated Participation and Impact In connection with the Company’s prior financing round in October 2025, 2,722,642 Class A ordinary shares were issued, with one Class A warrant and one Class B warrant issued ...

Company’s Capital and Strategic Focus Now Exclusively Focused on IM8 IM8 FY 2026 Revenue Projected to Reach $180 - $200 Million CHARLOTTE, N.C., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company, and parent of the IM8 premium health and longevity brand, today announced a strategic realignment to fully capitalize on the rapid growth of its consumer health brand, IM8. Prenetics ceased its daily Bitcoin purchasing activity ...

Core Viewpoint - Prenetics Global Limited has initiated a warrant exchange program to simplify its capital structure and reduce potential future dilution, with approximately 83.4% of outstanding Class A and Class B warrants participating in the exchange [1][2][3] Warrant Exchange Program - The program was developed based on feedback from institutional shareholders who supported consolidating legacy warrants into a cleaner structure [2] - The exchange agreements cover 4,539,722 of the 5,445,284 total Class A and Class B warrants, representing approximately 83.4% participation [3] Summary of the Warrant Exchange - The Company can exercise its forced-redemption right only after the registration statement for Class C warrants is effective and if Class A shares trade at or above $21.60 for ten consecutive trading days [4] - All eligible warrant holders were offered identical terms for participation in the exchange [5] Impact on Capital Structure - Approximately 4.54 million Class A and Class B warrants are expected to be exchanged for about 2.27 million Class C warrants [6] - Post-exchange, the total number of outstanding warrants is expected to be around 3.18 million, a reduction of approximately 42.0% from the original issuance in October 2025, with potential for up to 50% reduction if all holders participate [7] Strategic Rationale and Benefits - The exchange offers several benefits, including the consolidation of two legacy warrant classes into one Class C warrant with a lower exercise price of $18.00 and a two-year term [9] - Participation from the largest institutional investors indicates strong confidence in the revised structure and its long-term benefits [10] Company Overview - Prenetics is a leading health sciences company focused on health and longevity, with its IM8 brand achieving over $100 million in annual recurring revenue within 11 months of launch [11] - IM8 combines advanced science with natural ingredients to provide a holistic approach to health, featuring products like Daily Ultimate Essentials [12]

Prenetics Global Conference Summary Company Overview - **Company**: Prenetics Global (Ticker: PRE) - **Industry**: Consumer Healthcare, specifically in dietary supplements and diagnostics - **CEO**: Danny Young, co-founder since 2014 Key Points and Arguments Company Background and Growth - Prenetics started as a life sciences diagnostics testing company and pivoted to PCR testing during COVID, conducting over 28 million tests and generating $800 million in revenue over three years [2][3] - The company went public on NASDAQ in 2022 and is now positioned as the world's fastest-growing consumer healthcare brand [2] - Projected revenues for 2025 are approximately $90-$100 million, with expectations to reach $180-$200 million in 2026 driven by the IM8 brand [2][3] IM8 Brand - IM8 is a premium supplement brand co-founded with David Beckham, focusing on a scientific approach to health supplements [5][6] - The brand achieved $100 million in annual recurring revenue (ARR) within 11 months of launch, a record in the supplement industry [7][8] - Monthly revenue grew from $600,000 to $10 million over the past year, indicating strong growth momentum [8] - IM8 products are designed to simplify supplementation, offering multiple nutrients in a single powdered drink [10][11] Financial Metrics - The company has a strong balance sheet with approximately $70 million in cash and $117 million in total assets, including Bitcoin holdings [3][14] - The IM8 business is valued conservatively at $380 million, with a projected ARR run rate of $120 million [3][15] - The average order value increased from $110 to $145 after launching a new product, Daily Ultimate Longevity, indicating strong consumer demand [19] Market Position and Strategy - Prenetics operates in 41 countries, with a direct-to-consumer model that allows for better customer data utilization and marketing strategies [9][23] - The company plans to focus on two to three new product launches annually, maintaining a streamlined product line [18][19] - The management team emphasizes transparency and quality, with all products being NSF Certified for Sport and third-party tested [20] Divestment Strategy - Prenetics is divesting from legacy business units (Europa, CircleDNA, Insighta) to focus on the growth of IM8 [4][28][29] - The divestment of Insighta, valued at $70 million, is aimed at reallocating resources to enhance shareholder value [29] Bitcoin Strategy - The company initiated a Bitcoin treasury strategy to hedge against inflation, purchasing Bitcoin daily while maintaining a significant cash reserve [25][26] - The Bitcoin to cash ratio is expected to be around 30%-35%, ensuring operational liquidity [26] Competitive Landscape - Prenetics is positioned uniquely in the $700 billion global supplement market, with a focus on high-quality, scientifically-backed products [17][30] - The company believes it is undervalued in the market, trading at or slightly above cash and asset value, presenting a significant investment opportunity [30][31] Additional Insights - The company has received over 10,000 five-star reviews in just 11 months, indicating strong customer satisfaction [12] - High-profile endorsements from athletes like Aryna Sabalenka enhance brand visibility and credibility [12][21] - The management team has extensive experience in scaling businesses, which is crucial for navigating the competitive landscape [30] This summary encapsulates the key insights from the Prenetics Global conference, highlighting the company's growth trajectory, strategic focus, and market positioning.

Core Insights - Prenetics Global Limited is actively participating in upcoming investor conferences, showcasing its commitment to investor engagement and transparency [2][3]. Group 1: Investor Conferences - The company will attend The Benchmark Company's 14th Annual Discovery One-on-One Conference on December 4, 2025, where CEO Danny Yeung will hold one-on-one meetings with investors [2]. - Prenetics will also participate in Sidoti's Year End Virtual Investor Conference on December 10-11, 2025, with a formal presentation by CEO Danny Yeung on December 10 at 10:00 a.m. Eastern Time, followed by one-on-one meetings with CFO Stephen Lo [3]. Group 2: Company Overview - Prenetics is a leading health sciences company known for its IM8 brand, which has achieved $108 million in Annual Recurring Revenue (ARR) within 12 months of launch, marking the fastest growth in the supplement industry [5]. - The company has established a Bitcoin Treasury, purchasing 1 Bitcoin per day, totaling 501 BTC as of November 24, 2025, indicating its innovative approach at the intersection of health and digital assets [6]. Group 3: IM8 Brand - IM8, co-founded with David Beckham, offers a premium core nutrition product, Daily Ultimate Essentials, which replaces 16 different supplements in a single drink and is NSF Certified for Sport, non-GMO, and vegan [7].

Core Insights - Prenetics Global Limited, a health-tech and longevity company, has announced that its executive leadership team has made open market purchases of the company's common stock, indicating strong internal confidence in the company's future [1][5]. Executive Purchases - The executive team collectively acquired 111,911 shares for approximately $1,446,887 [2]. - CEO Danny Yeung purchased 40,118 shares for about $502,000 at an average price of $12.51 per share [3]. - CMO Rahul Ramchand bought 60,000 shares for approximately $793,972 at an average price of $13.23 per share [4]. - CFO Stephen Lo acquired 8,000 shares for about $100,915 at an average price of $12.61 per share [4]. - President of Americas David Vanderveen purchased 3,793 shares for approximately $50,000 at an average price of $13.15 per share [5]. Company Overview - Prenetics is a leading health sciences company focused on redefining health and longevity through its flagship brand IM8, co-founded with David Beckham [6]. - IM8 has achieved $100 million in Annual Recurring Revenue within 11 months of launch, marking the fastest growth in the supplement industry [6]. - Prenetics is the first consumer health company to establish a Bitcoin treasury, currently holding 501 BTC, and purchases 1 Bitcoin daily [7]. Product Information - IM8 offers a premium core nutrition product, Daily Ultimate Essentials, which is an all-in-one powder supplement designed to replace 16 different supplements [8].

Core Insights - Cantor Fitzgerald has reiterated its Overweight rating on Prenetics Global Limited, adjusting the 12-month price target to $31 from $32, reflecting updates related to the planned divestment of its Europa business while maintaining a positive long-term outlook on the company [1][2] Financial Performance - Prenetics reported a 3Q25 revenue of $23.6 million, representing approximately 568% year-over-year growth, with IM8 revenue reaching $17.2 million, up about 76% sequentially and achieving gross margins of around 60% [5] - The company has a customer payback period of approximately 3.9 months and an 80%+ subscription rate, indicating strong unit economics [5] - As of November 10, 2025, Prenetics holds approximately 387 BTC valued at around $41 million, contributing to total liquidity of approximately $120 million [5] Market Position and Valuation - Cantor views Prenetics as undervalued, with PRE trading at just 0.7× EV/2026E revenue compared to approximately 1.1× for consumer-health peers [2] - Cantor forecasts FY2026 revenue of approximately $217 million, driven by continued momentum from IM8 and international expansion [5] Management Commentary - CEO Danny Yeung emphasized that Cantor's ongoing research coverage highlights Prenetics' emergence as a global leader in health and longevity, reinforcing investor understanding of the significant opportunities ahead as IM8 scales internationally [2]

Financial Data and Key Metrics Changes - Total revenue surged 568% year over year to $23.6 million in Q3 2025, driven by IMA's 76% quarter-to-quarter growth [9] - Adjusted EBITDA loss improved from $6.5 million in Q1 to $2.1 million in Q3, indicating operational leverage and a clear path to profitability [12][17] - Cash increased to approximately $82 million and Bitcoin holdings valued at around $40 million, resulting in total liquidity of about $120 million with zero debt [7][18] Business Line Data and Key Metrics Changes - IMA achieved $100 million annual recurring revenue (ARR) in the last 11 months, with projections to reach $300 million ARR by the end of 2026 [6] - Subscription rate for IMA stands at 80%, with an average order value increasing by 36% quarter over quarter to $150 [10][11] - Gross margin improved to 60% from 52%, reflecting enhanced profitability [10] Market Data and Key Metrics Changes - International markets now account for 56.5% of total revenue, with the U.S. being the top market followed by Canada, the U.K., Australia, and Singapore [10] - IMA has achieved over 420,000 customer purchases across 31 countries, indicating strong global demand [9] Company Strategy and Development Direction - The company aims to create a new category at the intersection of health and wealth, targeting $1 billion in annual revenue by 2030 [6] - A strategic divestment of non-core assets is underway to focus resources on IMA, the highest margin growth engine [14] - The company is leveraging partnerships with high-profile individuals to enhance brand visibility and credibility [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $180-$200 million in revenue for 2026, driven by international expansion and new product launches [18] - The company is strategically choosing to scale aggressively rather than prioritize short-term profitability, aiming to capture maximum market share [18] Other Important Information - The company has initiated a Bitcoin accumulation strategy, purchasing one Bitcoin daily since August 1, which is part of a sustainable framework to build shareholder value [8] - The recent $44 million funding round attracted notable investors, enhancing the company's financial position [6] Q&A Session Summary Question: Impressive payback period of 3.9 months - Management explained that the payback period has improved from four to five months at launch to 3.9 months now, indicating marketing efficiencies and strong unit economics [19][20] Question: Strong growth in international markets - Management noted that the U.S. market share has decreased from 70% to 46.5%, with significant growth observed in Canada, Europe, the Middle East, and Southeast Asia [21] Question: Need for additional capital for expansion - Management stated that with current liquidity, there is no expectation of needing new capital for expansion, emphasizing operational flexibility from recent fundraising [22][24]

Core Insights - Prenetics Global Limited has launched Daily Ultimate Longevity, a supplement targeting all 12 hallmarks of aging, reinforcing IM8's rapid growth in the supplement industry [1][3][4] - IM8 has achieved a compound annual growth rate of 2,457%, with monthly revenue increasing from approximately $600,000 to $6.6 million within nine months [1][4] - The global longevity market is projected to reach $314 billion by 2030, positioning IM8 at the forefront of this expanding market [7] Company Overview - Prenetics is a leading consumer health sciences company, with IM8 being one of the fastest-growing supplement brands co-founded by David Beckham [1][11] - The company maintains a strong financial foundation with over $90 million in liquid assets, including approximately $60 million in cash and 255.4 Bitcoin valued at around $31.6 million [10] Product Details - Daily Ultimate Longevity is formulated with IM8's proprietary 5-Complex System, delivering therapeutic doses of clinically-validated ingredients in a powder format [3][5][8] - The product is designed to target key aging pathways such as cellular senescence and mitochondrial dysfunction, supported by human clinical research [5][6][8] - It is priced at $149 for a one-time purchase and $119 per month for subscription, reflecting its premium positioning in the market [9] Market Positioning - The launch of Daily Ultimate Longevity is seen as a category-defining innovation in the rapidly growing longevity market [7][8] - The product's formulation includes high-dose glycine, taurine, and other key ingredients aimed at comprehensive cellular support and energy enhancement [8][12]

Core Insights - Prenetics Global Limited reported a strong financial performance for Q1 2025, with revenue increasing by 336.5% year-over-year to $14.4 million, excluding ACT Genomics [3][7] - The company raised its full-year revenue outlook from $73 - $85 million to $80 - $100 million, reflecting accelerating momentum across its business units [4][13] - Prenetics has a robust cash position of $78 million, allowing for continued innovation and strategic initiatives, including a focus on cryptocurrency and Bitcoin adoption [6][12] Financial Highlights - Revenue from continuing operations was $17.3 million in Q1 2025, a 169.9% increase compared to Q1 2024 [7] - Gross profit from continuing operations reached $7.3 million, up 94.1% year-over-year [7] - Adjusted EBITDA loss from continuing operations was $(6.5) million, an increase of 59.4% compared to the previous year [7] Business Updates - The IM8 brand contributed $5.7 million in revenue for Q1 2025, with expectations of approximately $8.5 million in Q2, representing a 50% quarter-over-quarter increase [4][13] - IM8 has over 55,000 customers and has delivered more than 4.9 million servings of its flagship product [11] - The strategic review of ACT Genomics is nearing conclusion, with an announcement regarding ownership stake expected soon [5] Strategic Initiatives - The company is actively pursuing innovative treasury management approaches, including discussions on digital asset opportunities and Bitcoin adoption [6][12] - Prenetics aims to leverage its strong cash position to enhance its competitive positioning in the health tech sector through strategic crypto initiatives [6][12]